Michael A. Sheard
YOU?
Author Swipe
View article: Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma
Anti-CCL2 antibody combined with etoposide prolongs survival in a minimal residual disease mouse model of neuroblastoma Open
C–C motif chemokine ligand 2 (CCL2) is a monocyte chemoattractant that promotes metastatic disease and portends a poor prognosis in many cancers. To determine the potential of anti-CCL2 inhibition as a therapy for recurrent metastatic dise…
View article: Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC increase tumor engraftment and growth in xenograft model.
View article: Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC and BM-MSC induce activation of STAT3 and ERK1/2 signaling in NB cells
View article: Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
A: List of antibodies used in the study B: Clinical characteristics of patients from which CAF-MSC and BM-MSC were isolated.
View article: Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells Open
Supplementary Figure S1 shows that expression of natural cytotoxicity receptors and GD2 on neuroblastoma cells are not affected by TGFbeta1 or galunisertib.
View article: permission letter from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
permission letter from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Permission letter regarding inclusion of information of CHLA-255 C-Myc over-expression
View article: Supplementary Fig. 1-8 from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Supplementary Fig. 1-8 from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Targeting CD105+ Microenvironment cells enhances immunotherpy of Dinutuxmab with aNK cells against neuroblastoma
View article: Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Combination of ruxolitinib and trametinib inhibits the growth of subcutaneous NB tumors, cell proliferation and STAT3 and ERK1/2 activation in vivo.
View article: Supplementary Figure Legend, Tables 1 - 2 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy
Supplementary Figure Legend, Tables 1 - 2 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy Open
PDF file - 89K, Supplemental Table 1. List of antibodies used in this study. Supplemental table 2. Cytokines/chemokines excluded from the Luminex� panels.
View article: Data from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Data from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma Open
Purpose:Immunotherapy of neuroblastoma that remains after myeloablative chemotherapy with anti-GD2 antibody dinutuximab has increased the two-year event-free and overall survival of high-risk neuroblastoma patients; however, 40% of patient…
View article: Data from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Data from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Cancer-associated fibroblasts (CAF) have been suggested to originate from mesenchymal stromal cells (MSC), but their relationship with MSCs is not clear. Here, we have isolated from primary human neuroblastoma tumors a population of αFAP- …
View article: Supplementary Tables from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Supplementary Tables from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Supplementary Tables
View article: Supplementary Figure 6 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 6 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Cytokines and chemokines not up-regulated by NB-MSC interaction and lack of inhibition of STAT3 activation by anti-IL-6/IL-6R
View article: Data from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy
Data from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy Open
Purpose: Adoptive transfer of natural killer (NK) cells combined with tumor-specific monoclonal antibodies (mAb) has therapeutic potential for malignancies. We determined if large numbers of activated NK (aNK) cells can be grown ex vivo fr…
View article: Supplementary Figure S1. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure S1. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Characterization of CAF-MSC and BM-MSC isolated from different patients.
View article: Supplementary Table S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Supplementary Table S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells Open
Supplementary Table S1 is a list of antibodies used in the study. It has been updated to include antibodies used in experiments requested by reviewer #3.
View article: Figure S1 from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Figure S1 from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma Open
GD2 expression levels
View article: Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Supplementary Figure S1 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells Open
Supplementary Figure S1 shows that expression of natural cytotoxicity receptors and GD2 on neuroblastoma cells are not affected by TGFbeta1 or galunisertib.
View article: Supplementary Figures 1 - 4 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy
Supplementary Figures 1 - 4 from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy Open
PDF file - 1549K, Supplemental Figure 1. Cytokine and chemokine release from K562 Clone 9.mbIL21 aAPC-expanded effector cells after 24-hour incubation with neuroblastoma cell line CHLA-255-Fluc alone or with anti-GD2 antibody ch14.18. Supp…
View article: Supplementary Figure S3 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells
Supplementary Figure S3 from TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells Open
Supplementary Figure S3 presents meta-analyses of tumor growth in mice treated with and without galunisertib and dinutuximab.
View article: Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 5 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC and BM-MSC induce activation of STAT3 and ERK1/2 signaling in NB cells
View article: Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 7 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Combination of ruxolitinib and trametinib inhibits the growth of subcutaneous NB tumors, cell proliferation and STAT3 and ERK1/2 activation in vivo.
View article: Supplementary Figure 4 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure 4 from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC and BM-MSC enhance cell viability of NB cells in vitro and protect tumor cells from drug-induced apoptosis in vitro.
View article: Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Table A and B from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
A: List of antibodies used in the study B: Clinical characteristics of patients from which CAF-MSC and BM-MSC were isolated.
View article: Data from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy
Data from Growth and Activation of Natural Killer Cells <i>Ex Vivo</i> from Children with Neuroblastoma for Adoptive Cell Therapy Open
Purpose: Adoptive transfer of natural killer (NK) cells combined with tumor-specific monoclonal antibodies (mAb) has therapeutic potential for malignancies. We determined if large numbers of activated NK (aNK) cells can be grown ex vivo fr…
View article: Data from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells
Data from Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer Cells Open
Purpose:We determined whether elimination of CD105+ cells in the tumor microenvironment (TME) with anti-CD105 antibodies enhanced anti-disialoganglioside (GD2) antibody dinutuximab therapy of neuroblastoma when combined with activated natu…
View article: Supplementary Figure Legend from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Supplementary Figure Legend from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma Open
Supplemental Figure 1
View article: Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure S3. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
CAF-MSC increase tumor engraftment and growth in xenograft model.
View article: Supplementary Figure Legend from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma
Supplementary Figure Legend from Activated Natural Killer Cells in Combination with Anti-GD2 Antibody Dinutuximab Improve Survival of Mice after Surgical Resection of Primary Neuroblastoma Open
Supplemental Figure 1
View article: Supplementary Figure S1. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells
Supplementary Figure S1. from Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal Cells Open
Characterization of CAF-MSC and BM-MSC isolated from different patients.